Patience Needed On US Biosimilars, Says Samsung Bioepis’ Ko

Expectations For US Biosimilars ‘May Have Been Excessive’

 
• By David Wallace
  
Hourglass
The US biosimilars market will take time to mature, Ko insists • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business